Pfizer expands agreement with Aurobindo to 44 drugs from 5

Pfizer has expanded its agreement with Aurobindo to 44 drugs from five drugs. It has acquired rights to 39 generic drugs in the US and rights to 20 generic drugs in Europe and 11 in France. Vikas Dandekar of Pharmaasiannews.com reports in detail.

Sandoz of Novartis is the only company that has taken a full fledged dip into the world of generics. Pfizer is also taking this unconventional method, and so far as Aurobindo is concerned, the biggest thing that will happen is that eight of its US-approved FDA facilities, which were lying underutilized for some time now, will get utilized and as Aurbindo Chairman has also mentioned, it will give them some amount of earnings ability.

Out of these 39 products, most of are beaten down generics but a few will be high revenue earners.

Kelvin Cooper of Pfizer said that a few of them are big-sized but they did not want to give details about specific products. But obviously, when Greenstone of Pfizer is becoming the front end for Aurobindo’s product, it will definitely be a good reputation product and it will definitely have a better stint.